Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Claire BridelCyra E LeursZoë Y G J van LieropZoé L E van KempenIris DekkerHarry A M TwaalfhovenBastiaan MoraalFrederik BarkhofBernard M J UitdehaagJoep KillesteinCharlotte E TeunissenPublished in: Neurology (2021)
This study provides Class II evidence that serum NfL levels are not associated with disease progression in natalizumab-treated patients with RRMS.